Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pediatr Int ; 55(3): 320-7, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23461670

RESUMEN

BACKGROUND: This study was conducted to clarify whether respiratory stimulants used to treat apnea of prematurity (AOP) attenuate or aggravate hypoxia-induced neuronal damage. METHODS: A human neuroblastoma cell line, SH-SY5Y cells, and hippocampal slice cultures from rat pups were exposed to hypoxia to induce cell injury. The effects of respiratory stimulants on cell injury were evaluated. RESULTS: Theophylline and doxapram did not have any effects against cell injury induced by hypoxia in SH-SY5Y cells and hippocampal slice cultures of rat pups, while caffeine protected these cells and the slice cultures from hypoxia. The protective effects of caffeine in SH-SY5Y cells disappeared with co-treatment by the adenosine A2A receptor agonist, CGS21680, and were mimicked by the adenosine A2A R antagonist, SCH58261. Meanwhile, co-treatment with phosphatidylinositol 3-kinase/AKT pathway inhibitors did not affect the protective effects of caffeine. Hydroxy radical scavenging activity of caffeine were not observed at the concentrations that produced cytoprotective activity, and radical scavengers did not have any effects on the cell injury induced by hypoxia in SH-SY5Y cells. CONCLUSIONS: Caffeine significantly attenuated cell injury induced by hypoxia in SH-SY5Y cells and hippocampal slice cultures of rat pups, at least partly through A2A R antagonism. Caffeine can protect neuronal cells from injury induced by hypoxemia, and may be a beneficial treatment for AOP with neuroprotective potential.


Asunto(s)
Hipoxia de la Célula/efectos de los fármacos , Hipoxia de la Célula/fisiología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Hipocampo/efectos de los fármacos , Hipocampo/fisiopatología , Neuronas/efectos de los fármacos , Neuronas/fisiología , Fármacos del Sistema Respiratorio/farmacología , Antagonistas del Receptor de Adenosina A2/farmacología , Animales , Animales Recién Nacidos , Cafeína/farmacología , Línea Celular , Fármacos Neuroprotectores/farmacología , Ratas
2.
J Pharm Pharmacol ; 65(1): 102-14, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23215693

RESUMEN

OBJECTIVES: To establish whether aminophylline, administered at usual doses for rodents in pharmacological studies, induces brain injury in systemic hypoxaemia in guinea-pigs. METHODS: A hypoxaemia (partial oxygen tension of arterial blood (PaO2) = 40-60 mmHg) model was developed by low tidal volume mechanical ventilation in guinea-pigs. KEY FINDINGS: Under hypoxic conditions, aminophylline significantly increased the concentration of brain-specific creatine kinase in the serum in a dose- and time-dependent manner. A reduced number of hippocampal neuronal cells in the CA1 region, an increase in the concentration of neuron-specific enolase (NSE) in cerebrospinal fluid (CSF), an increase in lipid hydroperoxides and a decrease in the ratio of glutathione to glutathione disulfide in the brain tissues were also observed. These effects were not observed when aminophylline at the same doses was administered under normoxic conditions (PaO2 = 80-100 mmHg). There was no difference in either serum or CSF concentrations of theophylline between normoxic and hypoxic conditions. Another methylxanthine, caffeine, did not increase the concentration of NSE in CSF. CONCLUSIONS: Aminophylline potentially induces brain damage under hypoxic conditions. We suggest that aminophylline treatment has adverse effects in patients with hypoxaemia subsequent to respiratory disorders such as asthma.


Asunto(s)
Aminofilina/efectos adversos , Región CA1 Hipocampal/efectos de los fármacos , Hipoxia Encefálica/fisiopatología , Neuronas/efectos de los fármacos , Síndromes de Neurotoxicidad/etiología , Inhibidores de Fosfodiesterasa/efectos adversos , Antagonistas de Receptores Purinérgicos P1/efectos adversos , Aminofilina/administración & dosificación , Aminofilina/metabolismo , Aminofilina/farmacocinética , Animales , Antipirina/administración & dosificación , Antipirina/análogos & derivados , Antipirina/uso terapéutico , Región CA1 Hipocampal/metabolismo , Región CA1 Hipocampal/patología , Forma BB de la Creatina-Quinasa/sangre , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Edaravona , Depuradores de Radicales Libres/administración & dosificación , Depuradores de Radicales Libres/uso terapéutico , Glutatión/metabolismo , Cobayas , Infusiones Intravenosas , Peróxidos Lipídicos/metabolismo , Masculino , Proteínas del Tejido Nervioso/sangre , Proteínas del Tejido Nervioso/líquido cefalorraquídeo , Neuronas/metabolismo , Neuronas/patología , Síndromes de Neurotoxicidad/metabolismo , Síndromes de Neurotoxicidad/patología , Síndromes de Neurotoxicidad/prevención & control , Estrés Oxidativo/efectos de los fármacos , Inhibidores de Fosfodiesterasa/administración & dosificación , Inhibidores de Fosfodiesterasa/metabolismo , Inhibidores de Fosfodiesterasa/farmacocinética , Fosfopiruvato Hidratasa/líquido cefalorraquídeo , Antagonistas de Receptores Purinérgicos P1/administración & dosificación , Antagonistas de Receptores Purinérgicos P1/metabolismo , Antagonistas de Receptores Purinérgicos P1/farmacocinética , Teofilina/sangre , Teofilina/líquido cefalorraquídeo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA